GWPH News and Press, GW Pharmaceuticals Plc From 11/20/19

In case you missed it, last week was the earnings free-for-all in the cannabis industry that Wall Street and investors had patiently waited for. Unfortunately, things did not go as planned. Although it was a well-known fact that Canadian pot stocks have been hit hard by supply issues, and U.S...

If you're looking to invest in cannabis-focused biotech stocks , there aren't very many choices available. GW Pharmaceuticals (NASDAQ: GWPH) is the biggest alternative based on market cap. 22nd Century Group (NYSEMKT: XXII) is another biotech with an expanding cannabis program. Which o...

Source: Author based on company filings. Summary The CBD market is expected to boom over the next several years. After being fully legalized by the Farm Bill, the next step for CBD will be when the FDA issues guidelines clarifying the sale and marketing of CBD products for human consum...

GW Pharmaceuticals ( GWPH ) announced its Q3 2019 earnings recently. Its earnings beat analysts' expectations, but the stock still closed down by 17% based on this news. I believe that there is a good buying opportunity after this drop. For starters, the earnings were good as both EPS and ...

A year ago, cannabis was the hottest investment on the planet – and it's not hard to understand why. Although estimates vary wildly on Wall Street, the prevailing consensus is that worldwide marijuana revenue will grow fivefold to 18-fold between 2018 and 2030. That's led to some (pardo...

Delta, Kelowna, BC - November 11, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's edition of Investorideas.com potcastsCM - cannabis news and stocks ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . The event regularly racks up bigger sales than Black Friday and Cyber Monday combined, but Alibaba (BABA) already topped last year's ...

Two cannabis-based medicines - manufacturered by GW Pharmaceuticals (NASDAQ: GWPH ) - have been recommended for use on the NHS for the first time. More news on: GW Pharmaceuticals plc, Healthcare stocks news, Read more ...

GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal products (CBMPs) Cannabidiol oral solution and nabiximols are the first and on...

Investing legend Peter Lynch coined the term "10-bagger" to describe a stock that delivers a tenfold return. Relatively few stocks ever earn the moniker. But a couple of marijuana stocks have done just that and then some. Both of these stocks have turned an initial investment of $10,000 into ...